| Previous Section | Index | Home Page |
15 Jan 2009 : Column 959W—continued
Crown Prosecution Service
Rob Marris: To ask the Solicitor-General in respect of how many cases the Crown Prosecution Service in England and Wales (a) advised the police, (b) discontinued after charge but before trial and (c) proceeded to trial in (i) 2005, (ii) 2006 and (iii) 2007. [243064]
The Solicitor-General: The following table shows at (a) the number of defendants in respect of whom the Crown Prosecution Service (CPS) advised the police or took a pre-charge decision in each of the three years in question.
The table also shows the number of defendants prosecuted by the CPS, together with the outcome of proceedings. These cases include both those charged or summonsed by the police, and those in which a pre-charge decision to charge was made by the CPS. Case outcomes include at (b) the number and proportion of defendants whose case was dropped by the CPS before evidence was heard by a court, including those formally discontinued in advance of a hearing. Shown at (c) are the number and proportion which proceeded to a trial, together with the outcome of the trial. Finally, the table shows the number and proportion of defendants whose case resulted in a conviction (including guilty pleas as well as convictions after trial) and unsuccessful outcomes, representing all outcomes other than a conviction.
| Crown Prosecution Service case outcomes data | ||||||
| 2005 | 2006 | 2007 | ||||
| Volume | Percentage | Volume | Percentage | Volume | Percentage | |
| (1 )Administrative finalisations comprise outcomes where the defendant cannot be traced, or has died, or been found unfit to plead. (2 )Prosecutions dropped are all proceedings halted before evidence is heard. (3 )Trials comprise cases where the defendant pleaded not guilty and evidence was heard by the court. | ||||||
Rob Marris: To ask the Solicitor-General what the average time taken by Crown Prosecution Service lawyers in England and Wales (a) preparing a case for trial and (b) attending at trial was in (i) 2005, (ii) 2006 and (iii) 2007. [243065]
The Solicitor-General: The Crown Prosecution Service maintains no central record of the time committed by lawyers to the preparation of cases for trial or to trial attendance. The information is not recorded on individual case files.
Human Trafficking: Prosecutions
Andrew Rosindell: To ask the Solicitor-General what progress the Crown Prosecution Service has made in prosecuting those engaged in human trafficking. [247660]
The Solicitor-General:
The Crown Prosecution Service (CPS) is working to improve the number of prosecutions, and the number of offences prosecuted under human trafficking legislation is increasing year on year. The number of prosecutions should also increase further as
a result of our ratification of the Council of Europe Convention on Action against Trafficking in Human Beings in December 2008. The Convention will assist investigations and provide support for victims of trafficking in the course of criminal proceedings.
Mr. Bone: To ask the Solicitor-General how many people have been prosecuted by the Crown Prosecution Service for offences relating to the trafficking of people into the UK for sexual exploitation since 2003. [247798]
The Solicitor-General: The records held at discrete offence level by the Crown Prosecution Service (CPS) identify the number of offences of trafficking into the United Kingdom for sexual exploitation in which a prosecution commenced, rather than the number of defendants prosecuted. During the four years for which figures are available the number of these offences was as follows:
| Number | |
Health
Arthritis: Drugs
Mrs. Riordan: To ask the Secretary of State for Health if he will instruct the National Institute for Health and Clinical Excellence to take account of the effects on society and on public expenditure when evaluating treatments of rheumatoid arthritis which enable patients to continue to work or to return to work. [247296]
Dawn Primarolo: The process by which the National Institute for Health and Clinical Excellence (NICE) appraises drugs and treatments is a matter for the institute. NICE undertakes a wide consultation, on a regular basis, on the methods and processes in follows in health technology appraisal. The latest guidance to its methodologies was published on 23 June 2008 and details can be found on NICE’s website at:
The methodology guidance NICE uses takes account of the impact of treatments on publicly-funded social care costs and, where relevant, can look at health-related benefits to carers. NICE can also conduct sensitivity analyses to expose potentially significant impacts on other areas of public spending.
Mrs. Riordan: To ask the Secretary of State for Health what estimate he has made of the proportion of rheumatoid arthritis patients who fulfil the National Institute for Health and Clinical Excellence requirements for anti-TNF treatment but who do not receive anti-TNF treatment. [247297]
Dawn Primarolo: We have made no estimate of the number of people with rheumatoid arthritis meeting the National Institute for Clinical Excellence guidelines who are not receiving anti-TNF treatment.
Blood: Contamination
Jenny Willott: To ask the Secretary of State for Health how many haemophiliacs known to have been infected with HIV through contaminated blood products administered to them under NHS treatment are still alive; and if he will make a statement. [247048]
Dawn Primarolo: The number of haemophiliacs known to still be alive after being infected with HIV through contaminated blood products administered to them under national health service treatment is 345. In addition, there is a very small number of women with bleeding disorders still alive who have acquired HIV through this route.
Jenny Willott: To ask the Secretary of State for Health whether his Department is planning to respond to the forthcoming report by Lord Archer on contaminated blood and blood products and to its specific recommendations; and if he will make a statement. [247054]
Dawn Primarolo: We await Lord Archer's report with interest. We will decide whether and how the Department may need to respond when the report is available.
Cancer: Drugs
Mr. Baron: To ask the Secretary of State for Health when he expects the National Cancer Director to publish his evaluation of the National Institute for Health and Clinical Excellence approved cancer drug usage. [247106]
Dawn Primarolo: The National Cancer Director, Professor Mike Richards, has undertaken his third analysis of usage of cancer drugs approved by the National Institute for Health and Clinical Excellence. The findings were made available in chapter 4 of the first report of the Cancer Reform Strategy, “Cancer Reform Strategy: Maintaining momentum, building for the future—first annual report”, published on 1 December 2008. This document has already been placed in the Library.
| Next Section | Index | Home Page |